The diagnosis and medical management of advanced neuroendocrine tumors.
The DOI matches its Crossref record; 657 of the 670 references it cites were found in a registry or an index.
Abstract
Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that originate from endocrine glands such as the pituitary, the parathyroids, and the (neuroendocrine) adrenal, as well as endocrine islets within glandular tissue (thyroid or pancreatic) and cells dispersed between exocrine cells, such as endocrine cells of the digestive (gastroenteropancreatic) and respiratory tracts. Conventionally, NETs may present with a wide variety of functional or nonfunctional endocrine syndromes and may be familial and have other associated tumors. Assessment of specific or general tumor markers offers high sensitivity in establishing the diagnosis and can also have prognostic significance. Imaging modalities include endoscopic ultrasonography, computed tomography and magnetic resonance imaging, and particularly, scintigraphy with somatostatin analogs and metaiodobenzylguanidine. Successful treatment of disseminated NETs requires a multimodal approach; radical tumor surgery may be curative but is rarely possible. Well-differentiated and slow-growing gastroenteropancreatic tumors should be treated with somatostatin analogs or alpha-interferon, with chemotherapy being reserved for poorly differentiated and progressive tumors. Therapy with radionuclides may be used for tumors exhibiting uptake to a diagnostic scan, either after surgery to eradicate microscopic residual disease or later if conventional treatment or biotherapy fails. Maintenance of the quality of life should be a priority, particularly because patients with disseminated disease may experience prolonged survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With the combination of noninvasive and selected invasive modalities (particularly endoscopic ultrasound), most insulinomas are localized preoperatively (72, 78).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [72]
In the citing paper
“Although the results with a given method reflect the experience and expertise with that method at a given center, computed tomography, MRI, and transabdominal ultrasonography detect most insulinomas (71-73).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [72]
Citations
Cites
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Induction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
Brandi, M. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5658 · Cited by 2,031
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Gutmann, D. H. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550010065042 · Cited by 1,359
An analysis of 8305 cases of carcinoid tumors
Modlin, I. M., & Sandor, A. (2000) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2 · Cited by 1,200
The Complex of Myxomas, Spotty Pigmentation, and Endocrine Overactivity
CARNEY, J. A., GORDON, H., CARPENTER, P. C., SHENOY, B. V., & W. GO, V. L. (1985) · Medicine · doi:10.1097/00005792-198507000-00007 · Cited by 1,114
Research works printed but not linked: 3
- Krenning, 1994, Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide., Semin Oncol, 21, 6
- Janson, 2000, Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors., J Nucl Med, 41, 1514
- Bartsch, 1990, Treatment of metastatic carcinoid tumors by recombinant human interferon-α. Results from a phase II study., J Cancer Res Clin Oncol, 116, 305
Cited by
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Self-citationClinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Role of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Self-citationCurrent Status of Gastrointestinal Carcinoids
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N., & Shapiro, M. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.038 · Cited by 848
Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
Metz, D. C., & Jensen, R. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.047 · Cited by 816
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 763
“The neuroendocrine (NE) system includes endocrine glands, such as the pituitary, the parathyroids, and the NE adrenal, as well as endocrine islet tissue embedded within glandular tissue (thyroid or pancreatic) and scattered cells in the exocrine parenchyma, such as endocrine cells of the digestive and respiratory trac…”
BackgroundIsidori, A. M., Kaltsas, G. A., Pozza, C., Frajese, V., Newell-Price, J., Reznek, R. H., Jenkins, P. J., Monson, J. P., Grossman, A. B., & Besser, G. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1542 · Cited by 522
Self-citationJensen, R. T., Berna, M. J., Bingham, D. B., & Norton, J. A. (2008) · Cancer · doi:10.1002/cncr.23648 · Cited by 488
Kayani, I., Bomanji, J. B., Groves, A., Conway, G., Gacinovic, S., Win, T., Dickson, J., Caplin, M., & Ell, P. J. (2008) · Cancer · doi:10.1002/cncr.23469 · Cited by 477
“In patients with high-grade metastatic NET there is often limited somatostatin receptor expression and systemic chemotherapy may be favored over radionuclide therapy.(21) It is speculated that as a prelude to therapy dual imaging with (18)FFIGURE 1.”
BackgroundA review on the clinical uses of SPECT/CT
Mariani, G., Bruselli, L., Kuwert, T., Kim, E. E., Flotats, A., Israel, O., Dondi, M., & Watanabe, N. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1390-8 · Cited by 438
“Precise identification and localization of small tumour foci is difficult even with high-definition imaging modalities such as CT or ultrasound (US), with a reported low and widely variable sensitivity ranging between 13 and 85% [20, 21].”
BackgroundKennedy, A. S., Dezarn, W. A., McNeillie, P., Coldwell, D., Nutting, C., Carter, D., Murthy, R., Rose, S., Warner, R. R. P., Liu, D., et al. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31815e4557 · Cited by 424
“Conventional therapies have largely been considered palliative supportive care.(8) However, aggressive local treatments in the liver have demonstrated improvements in both symptomatic control and survival.”
BackgroundImaging of Neuroendocrine Tumors
Rufini, V., Calcagni, M. L., & Baum, R. P. (2006) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2006.03.007 · Cited by 376
Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor
Bettini, R., Partelli, S., Boninsegna, L., Capelli, P., Crippa, S., Pederzoli, P., Scarpa, A., & Falconi, M. (2011) · Surgery · doi:10.1016/j.surg.2011.02.022 · Cited by 358
Diagnosis and Management of Pituitary Carcinomas
Kaltsas, G. A., Nomikos, P., Kontogeorgos, G., Buchfelder, M., & Grossman, A. B. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2231 · Cited by 325
Self-citationImaging of Neuroendocrine Tumors
Heller, M. T., & Shah, A. B. (2011) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2011.02.011 · Cited by 329
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Chrisoulidou, A., Kaltsas, G., Ilias, I., & Grossman, A. B. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0074 · Cited by 314
“As there are no clinical, biochemical and histopathological differences between phaeochromocytomas and paragangliomas, these tumours will be regarded as the same entity in the context of this review and designated as chromaffincell tumours (Kaltsas et al. 2004b).”
InfluentialSelf-citationPanzuto, F., Boninsegna, L., Fazio, N., Campana, D., Pia Brizzi, M., Capurso, G., Scarpa, A., De Braud, F., Dogliotti, L., Tomassetti, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0688 · Cited by 285
NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor
Vinik, A. I., Woltering, E. A., Warner, R. R. P., Caplin, M., O'Dorisio, T. M., Wiseman, G. A., Coppola, D., & Go, V. L. W. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebaffd · Cited by 287
“5, the diagnosis is established,(1) if the patient is normocalcemic and free of pyloric obstruction and has normal renal function.(13) The 2006 European Neuroendocrine Tumor Society (ENETS) guidelines had cutoff values of greater than 10-fold elevation for FSG and gastric pH 2 or less.”
BackgroundEffects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies
Mazziotti, G., Floriani, I., Bonadonna, S., Torri, V., Chanson, P., & Giustina, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2332 · Cited by 227
Motivations and Methods for Analyzing Pulsatile Hormone Secretion
Veldhuis, J. D., Keenan, D. M., & Pincus, S. M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0005 · Cited by 223
Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
Hofland, J., Kaltsas, G., & de Herder, W. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz004 · Cited by 208
“Key examples from endocrine organs are parathyroid adenoma, medullary thyroid carcinoma, pheochromocytoma, and paraganglioma (3), whereas a reclassification of pituitary adenoma as a neuroendocrine tumor has also been proposed recently (4).”
BackgroundSelf-citationMeta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
Giustina, A., Mazziotti, G., Torri, V., Spinello, M., Floriani, I., & Melmed, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036411 · Cited by 201
“Results of this meta-analysis support the anti-tumor effects of octreotide, a molecule that has also been extensively investigated for treatment of neuroendocrine tumors in different organs [66].”
Beaumont, J. L., Cella, D., Phan, A. T., Choi, S., Liu, Z., & Yao, J. C. (2012) · Pancreas · doi:10.1097/mpa.0b013e3182328045 · Cited by 165
“N euroendocrine tumors (NETs) are a group of malignancies, including carcinoids and pancreatic islet-cell tumors, characterized by their production of peptides and secretion of hormones such as serotonin.(1) Annual age-adjusted incidence of NET in the United States in 2004 has been estimated at approximately 5.”
BackgroundZitzmann, K., De Toni, E. N., Brand, S., Göke, B., Meinecke, J., Spöttl, G., Meyer, H. H. D., & Auernhammer, C. J. (2007) · Neuroendocrinology · doi:10.1159/000100057 · Cited by 160
Boninsegna, L., Panzuto, F., Partelli, S., Capelli, P., Fave, G. D., Bettini, R., Pederzoli, P., Scarpa, A., & Falconi, M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.030 · Cited by 161
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
Vilar, E., Salazar, R., Pérez-García, J., Cortes, J., Öberg, K., & Tabernero, J. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-06-0074 · Cited by 161
“(2001) Paclitaxel 10 10 13 Kulke et al. (2004b) Gemcitabine 7 0 11.”
Marotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0269 · Cited by 161
Multimodal management of neuroendocrine liver metastases
Frilling, A., Sotiropoulos, G. C., Li, J., Kornasiewicz, O., & Plöckinger, U. (2010) · HPB · doi:10.1111/j.1477-2574.2010.00175.x · Cited by 159
Koukouraki, S. I., Strauss, L. G., Georgoulias, V., Eisenhut, M., Haberkorn, U., & Dimitrakopoulou‐Strauss, A. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0110-x · Cited by 153
“The diagnosis of neuroendocrine tumours (NETs) is quite difficult owing to the low malignancy and slow growth rate [1].”
BackgroundA Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management
Sultana, Q., Kar, J., Verma, A., Sanghvi, S., Kaka, N., Patel, N., Sethi, Y., Chopra, H., Kamal, M. A., & Greig, N. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155138 · Cited by 158
Biochemistry of neuroendocrine tumours
de Herder, W. W. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.12.002 · Cited by 153
Therapeutic Options for Gastrointestinal Carcinoids
Modlin, I. M., Latich, I., Kidd, M. S., Zikusoka, M. N., & Eick, G. N. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.12.008 · Cited by 154
Turaga, K. K., & Kvols, L. K. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20097 · Cited by 146
“Most GEP-NETs are nonfunctioning and present fairly late with mass effects, distant metastasis, or both (Table 3).(20,33) Delayed diagnosis by 5 to 7 years after the onset of symptoms is common and increases the likelihood of patients presenting with advanced or metastatic disease.”
BackgroundInfluentialRisk Factors for the Development and Progression of Carcinoid Heart Disease
Bhattacharyya, S., Toumpanakis, C., Chilkunda, D., Caplin, M. E., & Davar, J. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.12.025 · Cited by 154
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
Kaltsas, G. A., Papadogias, D., Makras, P., & Grossman, A. B. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01116 · Cited by 143
Self-citationChemoembolization and Bland Embolization of Neuroendocrine Tumor Metastases to the Liver
Ruutiainen, A. T., Soulen, M. C., Tuite, C. M., Clark, T. W. I., Mondschein, J. I., Stavropoulos, S. W., & Trerotola, S. O. (2007) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2007.04.018 · Cited by 143
“The release of these factors is the cause of significant morbidity and mortality, triggering symptoms such as hypoglycemia (ie, insulinomas), Zollinger-Ellison Syndrome (ie, gastrinomas), and carcinoid heart disease (ie, carcinoid tumors) ( 1 ,2).”
BackgroundResultInfluentialPrinciples of diagnosis and management of neuroendocrine tumours
Raphael, M. J., Chan, D. L. H., Law, C., & Singh, S. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.160771 · Cited by 155
Biochemical Testing for Neuroendocrine Tumors
Vinik, A. I., Silva, M. P., Woltering, G., W. Go, V. L., Warner, R., & Caplin, M. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181bc0e77 · Cited by 133
“Patients with noninsulinoma pancreatogenous hypoglycemia present with postprandial neuroglycopenia symptoms (within 4 hours of meal ingestion); have negative 72-hour fasting test; negative tumor localization studies; and on histological diagnosis, hypertrophy or nesidioblastosis rather than an insulinoma is found.(18,…”
BackgroundPanzuto, F., Fonzo, M. D., Iannicelli, E., Sciuto, R., MAINI, C. L., Capurso, G., Milione, M., Cattaruzza, M. S., Falconi, M., David, V., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj113 · Cited by 138
Zitzmann, K., von Rüden, J., Brand, S., Göke, B., Lichtl, J., Spöttl, G., & Auernhammer, C. J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.018 · Cited by 143
“At the time of diagnosis, the majority of NETs have already metastasized, accounting for a rather low 5-year survival rate of less than 50% [1,2].”
BackgroundLymph Nodes and Survival in Pancreatic Neuroendocrine Tumors
Krampitz, G. W., Norton, J. A., Poultsides, G. A., Visser, B. C., Sun, L., & Jensen, R. T. (2012) · Archives of Surgery · doi:10.1001/archsurg.2012.1261 · Cited by 129
“8) [14-69]a Age at surgery, mean (SEM) [range], y 49.”
BackgroundNeuroendocrine Neoplasms of the Appendix: A Review of the Literature
Moris, D., Tsilimigras, D. I., Vagios, S., Ntanasis‐Stathopoulos, I., Karachaliou, G. S., Papalampros, A., Alexandrou, A. P., Blazer, D. G., & Felekouras, E. S. (2018) · Anticancer Research · doi:10.21873/anticanres.12264 · Cited by 151
Koukouraki, S. I., Strauss, L. G., Georgoulias, V., Schuhmacher, J., Haberkorn, U., Karkavitsas, N. S., & Dimitrakopoulou‐Strauss, A. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-0006-1 · Cited by 127
“Neuroendocrine tumours (NETs) originate mostly from the gastroenteropancreatic (GEP) tract and express specific receptorslikeamineandpeptidereceptors(somatostatin,vasointestinal peptide receptors, bombesin, cholecystokinin, gastrin and/or substance P) [ 1 ].”
BackgroundKalinowski, M., Dreßler, M., König, A. O., El-Sheik, M., Rinke, A., Höffken, H., Gress, T. M., Arnold, R., Klose, K., & Wagner, H. (2009) · Digestion · doi:10.1159/000209849 · Cited by 126
From somatostatin to octreotide LAR: evolution of a somatostatin analogue
Anthony, L. B., & Freda, P. U. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903328959 · Cited by 124
Survival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based Study
Lepage, C., Rachet, B., & Coleman, M. P. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.006 · Cited by 129
Faggiano, A., Ferollà, P., Grimaldi, F., Campana, D., Manzoni, M. F., Davì, M. V., Bianchi, A., Valcavi, R., Papini, E., Giuffrida, D., et al. (2012) · PubMed · doi:10.3275/8102 · Cited by 123
Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
Kanakis, G., & Kaltsas, G. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2012.12.006 · Cited by 127
Self-citationGastrointestinal neuroendocrine tumors
Öberg, K. E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq290 · Cited by 121
“The first controlled study of octreotide LAR for treating carcinoid syndrome was conducted in 93 patients with NETs over at least 20 weeks [24].”
BackgroundMethodRole of biomarker tests for diagnosis of neuroendocrine tumours
Hofland, J., Zandee, W. T., & de Herder, W. W. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0082-5 · Cited by 126
Neuroblastoma and Other Neuroendocrine Tumors
Howman-Giles, R. B., Shaw, P. J., Uren, R. F., & Chung, D. K. V. (2007) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2007.02.009 · Cited by 126
Maroun, J. A., Kocha, W., Kvols, L. K., Bjarnason, G. A., Chen, E., Germond, C. J., Hanna, S. S., Poitras, P., Rayson, D., Reid, R. H., et al. (2006) · Current Oncology · doi:10.3390/curroncol13020006 · Cited by 128
Paraneoplastic syndromes secondary to neuroendocrine tumours
Kaltsas, G., Androulakis, I. I., de Herder, W. W., & Grossman, A. B. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0024 · Cited by 118
“…not restricted only to NETs, scintigraphy with 111In-labelled octreotide (Octreoscan) has offered a highly sensitive tool which, when used in the relevant clinical setting, identifies and localises the tumour in patients with NETs (Krenning et al. 1993, Olsen et al. 1995, Kaltsas et al. 2004a; Fig.”
BackgroundMethodInfluentialSelf-citationCapurso, G., Lattimore, S., Crnogorac‐Jurcevic, T., Panzuto, F., Milione, M., Bhakta, V., Campanini, N., Swift, S. M., Bordi, C., Fave, G. D., et al. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01153 · Cited by 115
“In fact, in some patients, the tumour may remain unchanged for a long period, even without treatment, whereas in others the tumour grows rapidly regardless of anti-proliferative treatment (Kaltsas et al. 2004).”
BackgroundYang, X., Yang, Y., Li, Z., Chen, C., Yang, T., Wang, C., Liu, L., & Liu, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124884 · Cited by 117
“The particular characteristic that distinguishes NETs from other solid malignancies is that NETs are composed of specialized cells that have the ability to produce, store, and secrete bioactive amines and peptide hormones [4].”
BackgroundAnatomic and Functional Imaging of Metastatic Carcinoid Tumors
Scarsbrook, A. F., Ganeshan, A., Statham, J., Thakker, R. V., Weaver, A., Talbot, D. C., Boardman, P., Bradley, K. M., Gleeson, F. V., & Phillips, R. R. (2007) · Radiographics · doi:10.1148/rg.272065058 · Cited by 103
Pancreatic insulinoma: current issues and trends.
Vaidakis, D., Karoubalis, J., Παππά, Θ., Piaditis, G. P., & Zografos, G. N. (2010) · Hepatobiliary & pancreatic diseases international · Cited by 112
The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors
Ramirez, R. A., Beyer, D. T., Chauhan, A., Boudreaux, J. P., Wang, Y., & Woltering, E. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0470 · Cited by 100
Paraneoplastic endocrine syndromes
Dimitriadis, G. K., Angelousi, A. G., Weickert, M. O., Randeva, H. S., Kaltsas, G., & Grossman, A. B. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0036 · Cited by 108
Self-citationThomas, D., Tsolakis, A. V., Grozinsky‐Glasberg, S., Fraenkel, M., Alexandraki, K., Sougioultzis, S., Gross, D. J., & Kaltsas, G. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0836 · Cited by 105
Self-citationThe Next Generation of Positron Emission Tomography Radiopharmaceuticals in Oncology
Rice, S. L., Roney, C. A., Daumar, P., & Lewis, J. S. (2011) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.02.002 · Cited by 96
Appendiceal neuroendocrine neoplasms: diagnosis and management
Alexandraki, K., Kaltsas, G., Grozinsky‐Glasberg, S., Chatzellis, E., & Grossman, A. B. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0310 · Cited by 96
“CgA is currently the most useful general biomarker available for the diagnosis of GI-NENs because elevations in CgA have been found to predict a relapse that may precede radiological detection as it is co-secreted by the majority of NE tumoural cells and persists after malignant transformation (Kaltsas et al. 2004).”
BackgroundMethodInfluentialSelf-citationFazio, N., de Braud, F., Fave, G. D., & Öberg, K. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl144 · Cited by 95
“In rare cases an atypical carcinoid syndrome can be present [8], particularly in patients with foregut carcinoid tumors.”
BackgroundThe Management of Neuroendocrine Tumours: Current and Future Medical Therapy Options
Öberg, K. E. (2011) · Clinical Oncology · doi:10.1016/j.clon.2011.08.006 · Cited by 90
Management of Medullary Thyroid Carcinoma
Jiménez, C., Hu, M. I.-N., & Gagel, R. F. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.03.001 · Cited by 89
“However, a complete remission has never been observed, and it apparently has no effect on survival rates [61].”
BackgroundPavel, M. E., Singh, S., Strosberg, J., Bubuteishvili‐Pacaud, L., Degtyarev, E., Neary, M. P., Carnaghi, C., Tomášek, J., Wolin, E. M., Raderer, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30471-0 · Cited by 93
Tessonnier, L., Sebag, F. A., Ghander, C., Micco, C. D., Reynaud, R., Palazzo, F. F., Conte‐Devolx, B., Henry, J. F., MUNDLER, O., & Taïeb, D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1357 · Cited by 87
“less than 1 cm in diameter and can be located anywhere in the pancreas (1, 2).”
BackgroundCT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification
Rha, S. E., Jung, S. E., Lee, K. H., Ku, Y. M., Byun, J. Y., & Lee, J. M. (2007) · European Journal of Radiology · doi:10.1016/j.ejrad.2007.02.036 · Cited by 91
“owever, it is a misnomer because it is not evident that they ll originate from pancreatic islets; especially non-functioning ndocrine tumors and some functioning tumors, such as gasrinoma and VIPoma originate from the gastrointestinal tract utside the pancreas [1].”
BackgroundEzziddin, S., Logvinski, T., Yong-Hing, C. J., Ahmadzadehfar, H., Fischer, H., PALMEDO, H., Bucerius, J. A., Reinhardt, M. J., & Biersack, H. (2006) · PubMed · Cited by 86
Malignant pheochromocytoma: new malignancy criteria
de Wailly, P., Oragano, L., Radé, F., Beaulieu, A., Arnault, V., Levillain, P., & Kraimps, J. L. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0850-3 · Cited by 93
Plöckinger, U., & Wiedenmann, B. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.01.002 · Cited by 85
ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors
Kos‐Kudła, B., O’Toole, D., Falconi, M., Gross, D., Klöppel, G., Sundin, A., Ramage, J. K., Öberg, K., Wiedenmann, B., Komminoth, P., et al. (2010) · Neuroendocrinology · doi:10.1159/000287255 · Cited by 89
“Genetics Hereditary predisposition to the development of bone and lung metastases has not been proven. Some inherited disorders are associated with GEP and pulmonary NET, e.g. multiple endocrine neoplasia type I, von Hippel-Lindau disease and neurofibromatosis 1. Minimal Consensus Statement on Histopathology and Genet…”
MethodCurrent best practice in the management of neuroendocrine tumors
Tsoli, M., Chatzellis, E., Koumarianou, A. A., Kolomodi, D., & Kaltsas, G. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818804698 · Cited by 93
Self-citationA tale of pituitary adenomas: to NET or not to NET
Ho, K. K. Y., Fleseriu, M., Wass, J. A. H., van der Lely, A., Barkan, A. L., Giustina, A., Casanueva, F. F., Heaney, A. P., Biermasz, N. R., Strasburger, C. J., et al. (2019) · Pituitary · doi:10.1007/s11102-019-00988-2 · Cited by 80
Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome
Clement, D., Ramage, J. K., & Srirajaskanthan, R. (2020) · Journal of Oncology · doi:10.1155/2020/8341426 · Cited by 86
“+e palpitations can be short in duration or persist for longer periods of time, up to 30 minutes [19, 29].”
BackgroundClinical Presentation and Diagnosis of Neuroendocrine Tumors
Vinik, A. I., & Chaya, C. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.08.006 · Cited by 85
Walter, T., Chardon, L., Chopin‐Laly, X., Raverot, V., Caffin, A.-G., Chayvialle, J., Scoazec, J., & Lombard‐Bohas, C. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.11.005 · Cited by 79
Role of PET/CT in the functional imaging of endocrine pancreatic tumors
Rufini, V., Baum, R. P., Castaldi, P., Treglia, G., Gaetano, A. M. D., Carreras, C., Kaemmerer, D., Hommann, M., Hörsch, D., Bonomo, L., et al. (2012) · Abdominal Imaging · doi:10.1007/s00261-012-9871-9 · Cited by 75
Chatzellis, E., Angelousi, A. G., Daskalakis, K., Tsoli, M., Alexandraki, K., Wachuła, E., Meirovitz, A., Maimon, O., Grozinsky‐Glasberg, S., Gross, D., et al. (2019) · Neuroendocrinology · doi:10.1159/000500135 · Cited by 74
Self-citationCarcinoid syndrome: diagnosis and medical management
van der Lely, A. J., & Herder, W. W. D. (2005) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302005000500028 · Cited by 73
Role of 68Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours
Kumar, R., Sharma, P., Garg, P. K., Karunanithi, S., Naswa, N., Sharma, R., Thulkar, S. P., Lata, S., & Malhotra, A. (2011) · European Radiology · doi:10.1007/s00330-011-2199-y · Cited by 72
“Some biochemical markers that are identifiable in body fluids suggest specific tumours, whereas others are common to several pancreatic NET subtypes [2, 3].”
BackgroundInfluentialÖberg, K. (2012) · Theranostics · doi:10.7150/thno.3931 · Cited by 77
“Other neuroendocrine pancreatic tumors, such as glucagonomas and VIPomas, express type 2 somatostatin receptors in about 60–70% of patients.[10] Thyroid medullary carcinomas and pheochromocytomas also express somatostatin receptors type 2 in about 40–60%”
BackgroundThe Zollinger–Ellison Syndrome: Dangers and Consequences of Interrupting Antisecretory Treatment
Poitras, P., Gingras, M., & Rehfeld, J. F. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.012 · Cited by 74
Pathology – Grading and staging of GEP-NETs
Capelli, P., Fassan, M., & Scarpa, A. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.01.003 · Cited by 71
“Ki67 index is also one of the parameters considered in the decision tree of therapeutic algorithms [89], and different cut-off values have been suggested for the selection of chemotherapeutic indications in individual patients undergoing tumour progression [18,90–92].”
BackgroundLimouris, G. S., Chatziioannou, A. N., Kontogeorgakos, D. C., Mourikis, D., Lyra, M., Dimitriou, P., Stavraka, A., Gouliamos, A. D., & Vlahos, L. J. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0779-0 · Cited by 70
Ferollà, P., Faggiano, A., Grimaldi, F., Ferone, D., Scarpelli, G., Ramundo, V., Severino, R., Bellucci, M. C., Camera, L., Lombardi, G., et al. (2012) · PubMed · doi:10.3275/7869 · Cited by 69
Rothenstein, J., Cleary, S. P., Pond, G. R., Dale, D., Gallinger, S., Moore, M. J., Brierley, J. D., & Siu, L. L. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31807a2f49 · Cited by 75
“Palliative chemotherapy has not consistently conferred a survival benefit in NET.(8) In recent years, new therapeutic options for NET have been developed, including radioactive-labeled somatostatin analogues, radiofrequency ablation, and hepatic artery embolization.”
BackgroundInfluentialSomatostatin receptor imaging for neuroendocrine tumors
de Herder, W. W., Kwekkeboom, D. J., Feelders, R. A., van Aken, M. O., Lamberts, S. W. J., van der Lely, A. J., & Krenning, E. P. (2006) · Pituitary · doi:10.1007/s11102-006-0270-5 · Cited by 72
“tic value in some patients with metastatic medullary thyroid carcinoma [ 21 ].”
BackgroundEffect of hormone secretory syndromes on neuroendocrine tumor prognosis
Zandee, W. T., Kamp, K., van Adrichem, R. C. S., Feelders, R. A., & de Herder, W. W. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0538 · Cited by 72
“SSAs can be administered pre-operatively to aid in this process and simultaneously low-molecular-weight heparins should be administered for prevention of thrombosis (Kaltsas et al. 2004).”
BackgroundFaggiano, A., Sabourin, J., Ducreux, M. P., Lumbroso, J., Duvillard, P., Leboulleux, S., Dromain, C., Colao, A., Schlumberger, M. J., & Baudin, É. (2007) · Cancer · doi:10.1002/cncr.22791 · Cited by 68
“Hormone secretion, tailored imaging (including functional imaging), and association as part of an inherited syndrome represent major features of NETs.(1) Regarding their prognostic features, pathologic differentiation has emerged as a major parameter.”
BackgroundInfluentialMedical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours
Dimitriadis, G. K., Weickert, M. O., Randeva, H. S., Kaltsas, G., & Grossman, A. B. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0200 · Cited by 67
“Uncontrolled diarrhoea may be debilitating causing dehydration, electrolyte abnormalities, vitamin deficits and hypoproteinaemia (Kaltsas et al. 2004).”
BackgroundInfluentialSelf-citationGastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy
Alexandraki, K., & Kaltsas, G. (2011) · Endocrine · doi:10.1007/s12020-011-9562-2 · Cited by 69
“However, within these subgroups the biological and clinical characteristics vary considerably [3, 22].”
BackgroundResultInfluentialSelf-citationGagliano, T., Bellio, M., Gentilin, E., Molè, D., Tagliati, F., Schiavon, M., Cavallesco, N. G., Andriolo, L. G., Ambrosio, M. R., Rea, F., et al. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0042 · Cited by 68
“2000), but is not feasible for large, infiltrating, and metastatic disease (Gregory et al. 2004).”
BackgroundReceptor PET/CT Imaging of Neuroendocrine Tumors
Baum, R. P., Prasad, V., Hommann, M., & Hörsch, D. (2008) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-31203-1_18 · Cited by 66
Endocrine Tumours: Epidemiology of malignant digestive neuroendocrine tumours
Lepage, C., Bouvier, A., & Faivre, J. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0418 · Cited by 67
A simplified prognostic system for resected pancreatic neuroendocrine neoplasms
Ballian, N., Loeffler, A. G., Rajamanickam, V., Norstedt, P., Weber, S. M., & Cho, C. S. (2009) · HPB · doi:10.1111/j.1477-2574.2009.00082.x · Cited by 64
“Perhaps as a result of increased awareness and improved diagnostic capabilities, their prevalence has increased substantially over the last 25 years.(3) Although usually indolent, the biological behaviour of pancreatic neuroendocrine neoplasms ranges from benign to frankly malignant.”
BackgroundRisk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors
Panzuto, F., Campana, D., Fazio, N., Brizzi, M. P., Boninsegna, L., Nori, F., Meglio, G. D., Capurso, G., Scarpa, A., Dogliotti, L., et al. (2011) · Neuroendocrinology · doi:10.1159/000334038 · Cited by 63
Luster, M., Karges, W., Zeich, K., Pauls, S., Verburg, F. A., Dralle, H., Glatting, G., Buck, A. K., Solbach, C., Neumaier, B., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1294-7 · Cited by 64
“Conventional morphological imaging, including computed tomography (CT), detects PHEOs with 93–100% sensitivity, as most of these tumors exceed 2 cm in diameter [3].”
Method
Metadata
- Authors
- Kaltsas, G. A., Besser, G. M., & Grossman, A. B.
- Affiliations
- St Bartholomew's Hospital (GB)
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2004-06-01
- Volume
- 25
- Issue
- 3
- Pages
- 458-511
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2031301095
- Semantic Scholar
- b09a37699a89446c4662f1bc87eb975bf31118b7
- Cited by
- 674
- References
- 670
- Citations by year
- 2026: 4 · 2025: 19 · 2024: 17 · 2023: 26 · 2022: 17 · 2021: 23 · 2020: 23 · 2019: 24 · 2018: 31 · 2017: 27 · 2016: 34 · 2015: 46 · 2014: 30 · 2013: 37 · 2012: 49
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- neuroendocrine tumors, diagnosis, tumor markers, endocrine syndromes, somatostatin analogues, MIBG scintigraphy, endoscopic ultrasound, interferon-alpha, chemotherapy, radionuclide therapy, multimodal therapy, quality of life
- MeSH terms
- Adrenal Gland Neoplasms, Animals, Antineoplastic Combined Chemotherapy Protocols, Gastrointestinal Neoplasms, Humans, Pancreatic Neoplasms, Parathyroid Neoplasms, Pituitary Neoplasms, Prognosis, Quality of Life, Sensitivity and Specificity, Somatostatin, Thyroid Neoplasms, Tomography, X-Ray Computed, Biomarkers, Tumor, Interferon-alpha, Carcinoma, Neuroendocrine, Neuroendocrine Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.